Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Kaletra

Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 15–16

HOS-108886 · Präparat HOS-093083

15 Dabigatran etexilate, Dabigatran etexilate, Clinical monitoring and/or dose Edoxaban Edoxaban: reduction of the direct oral Serum concentrations may be anticoagulants (DOAC) should be increased due to P-gp inhibition considered when a DOAC by lopinavir/ritonavir. transported by P-gp but not metabolised by CYP3A4, including dabigatran etexilate and edoxaban, is co-administered with Kaletra. Anticonvulsants Phenytoin Phenytoin: Caution should be exercised in Steady-state concentrations was administering phenytoin with moderately decreased due to Kaletra. CYP2C9 and CYP2C19 induction by lopinavir/ritonavir. Phenytoin levels should be monitored when co-administering Lopinavir: with Kaletra. Concentrations are decreased due to CYP3A induction by When co-administered with phenytoin. phenytoin, an increase of Kaletra dosage may be envisaged. Dose adjustment has not been evaluated in clinical practice. Carbamazepine and Carbamazepine: Caution should be exercised in Phenobarbital Serum concentrations may be administering carbamazepine or increased due to CYP3A phenobarbital with Kaletra. inhibition by lopinavir/ritonavir. Carbamazepine and phenobarbital Lopinavir: levels should be monitored when Concentrations may be decreased co-administering with Kaletra. due to CYP3A induction by carbamazepine and phenobarbital. When co-administered with carbamazepine or phenobarbital, an increase of Kaletra dosage may be envisaged. Dose adjustment has not been evaluated in clinical practice

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): phenobarbital (HOS-085617) carbamazepine (HOS-085618) edoxaban (HOS-086234) dabigatran etexilate (HOS-086233) phenytoin (HOS-084531)